Ilan Uchitel, CAPS Medical - Treating Tumors with Non-Thermal Atmospheric Plasma | LSI USA '24

Ilan Uchitel  0:00  
Hello everybody, my name is Ilan Uchitel and I'm the CEO and co founder of CAPS medical, we're developing a technology which will allow us to selectively target cancer cells without damaging the healthy tissue surrounding them to minimal invasive procedures. And we believe this will change the way the solid tumors are treated in the future. Cancer claims over nine and a half million lives annually making it the leading cause of death. conventional cancer therapies usually damage the healthy cells which surround the tumor, leading to life altering side effects and increase mortality. We believe that without technology, we will be able to target cancer cells from innovative procedures in to address this problem by leaving the healthy tissue surrounding the tumor completely undamaged. Our proprietary and app technology uses non thermal plasma, which is a stream of an ionized gas delivered to the tumor it nearing temperature to selectively kill cancer cells and causes stress selectively to cancer cells without causing thermal or other damage to the surrounding healthy tissue. By generating reactive oxygen and nitrogen species, we generate in apoptotic response in cancer cells, leading to the pre programmed cell death, which aligns recruits the Innate system that specifically targets similar cancer cells in the surrounding area. Over 15 years of clinical research has demonstrated the efficacy of non thermal plasmas to selectively destroy various types of cancer. The problem is that the existing devices on the market today are just too large and too energetic to be used inside the body where they're needed the most. Which brings us to capsule medical innovation. Our system is the first one that has a device small enough to be used inside the body. We have a small diameter flexible probe that can be applied for working channel of existing minimally invasive tools is a keyhole procedure which is completely safe, it doesn't cause cutting charring abrasion, or any damage to the healthy tissue on the access and around the tumor. It allows us a real time precise monitoring of the energy delivered to the tumor and it's very safe distraction. The system consists of a console and a disposable procedure kit, which will be our main revenue driver. Having a small diameter flexible probe makes us a natural fit to the minimum invested ecosystem, which put us in focus of interest of all the large players in the market. We already have one strategic invested in the company and the other one committed to invest. In our vision, we say our street in a variety of tumors all over the body in the scopic Lee bronchoscopic year through two cars and needles, we can assemble the technology on robotic platforms and we can always apply superficially. Our initial treatment indication is non muscle invasive bladder cancer anyway, BC. Bladder cancer is the sixth most common cancer worldwide. With over 1.6 million people living with the disease. Usually bladder cancer isn't cured. The higher recurrence rate makes better cancer, the most expensive cancer to treat across patient lifetime resulting in over seven and a half billion dollars across US and Europe alone. The standard of care for treating nfbc Hasn't principally changed over the past several decades. The tumors have been treated and retreated using a very traumatic resection called Dr. Beatty, which has high percentage of associated side effects. Then the resection is supplemented by a series of intravesical chemotherapy and immunotherapy installations. We have recently completed a first of its kind in the scopic clinical study in which we have treated 60 tumors across 28 patients instead of resection. 85% of the treated tumors have disappeared following the single treatment. Over a follow up period of one year we have seen no local recurrence of the treated tumors. We had no diversity with adverse events, no cutting, no bleeding the cheering the patients went home a couple hours after the procedure on the same day. This demonstrates the ability of our technology to preserve the healthy vital tissue as compared to the resection which leave the damaging scar in damages this vital organ. For nm ADC, the treatment is delivered through working channel of a standard SR scope by utilizing existing CPT codes. We are are working to deliver the technology as in office procedure and avoid surgery hospitalization Anastasia completely. Then when the device is clear to market, we will proceed to additional indications such as reducing installations, addressing high grades of tumors and also expanding traditional treatment indications. Following a series of discussions with the FDA, they have been very supportive that technology and grant does a very straightforward pathway to clearing the device. The pathway will include a pivotal study for NMI BC, which will begin during this year, we have CEE clearance slated for 2025 and FDA clearance for 2026. We're also working to expand the dedication to additional types of cancer, such as lung cancer is a foggy LGI and additional cancers. In a series of preclinical studies, we haven't encountered any resistance to end up by any tested cell lines. In addition to that, we have also already demonstrated our ability to deliver the plasma to the desired location across various indications for once the stomach and many many others. The company has three granted patents. In addition to 30 patent applications in the various stages worldwide will also have a license the exclusive a grooming for additional family of patents from the Technion. Our team has an extensive experience leadership experience in the healthcare industry and a proven track record. And our team is supported by world renowned experts with great cancer care experience, who also allows access to world leading institutions and clinical sites. To date, the company has raised $11 million from a strategic investor, private investors and non dilutive grant. We're now in the process of raising an $18 million funding round, which will allow us to conduct the pivotal study to obtain seeing FDA clearance and to address additional indications. Well, as I mentioned before, have additional strategic investor who is committed to invest as part of this funding round. So our proprietary and treatment is a minimally invasive selective oncology therapy, which is proven to be applicable to a wide range of tumors. We have promising clinical data, it clear go to market strategy with a huge addressable market. We have an experienced team in diverse supported by world renowned experts in leading academic institutions. And together we can make a difference in how cancer is treated in the future. Thank you so much.